曲美他嗪对冠心病心力衰竭患者血浆氮末端脑钠肽水平及运动耐量的影响

目的观察曲美他嗪对冠状动脉粥样硬化性心脏病（冠心病）心力衰竭（心衰）患者血浆氮末端脑钠肽前体（NT．proBNP）水平及运动耐量的影响。方法冠心病心衰患者82例，完全随机分为曲美他嗪组及常规治疗组各41例，于开始治疗前及药物治疗6个月后测定NT-proBNP，并行超声心动图检查和6min步行试验，对2组不同时段相关数据进行比较。结果治疗后曲美他嗪组与治疗前及与常规治疗组治疗后相比，NT-proBNP水平明显下降（P〈0．05），左心室舒张末期容积明显缩小，而左心室射血分数显著增加（P〈0．05）；6min步行距离显著增加（P〈0．05）。结论曲美他嗪可改善冠心病心衰患者运动耐量，有效降低血浆NT-proBNP水平。

Influence of trimetazidine therapy on N-terminal pro-brain natriuretic peptide and exercise tolerance in patients with congestive heart failure caused by coronary heart disease

Objective To observe the influence of trimetazidine therapy on N-terminal pro-brain natriuretic peptide (NT-proBNP) and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease. Methods A total of 8 patients with congestive myocardial failure caused by coronary heart disease were randomized into trimetazidine group and routine therapy group, The levels of NT-proBNP, 2-dimensional echocardiography (DE) were detected and 6-mintute walk test was done for all patients at the baseline and 6 months after the therapy. Results The levels of NT-proBNP and LVEDV were significantly lower(P<0.05), but LVEF became higher (P<0.05), and the mean distance of 6-mintute walk test significantly increased (P<0.05) in trimetazidine group than those in routine therapy group and the baseline. Conclusion With trimetazidine therapy,the level of NT-proBNP decreases in patients with coronary heart disease complicated with congestive myocardial failure, meanwhile paitent's exercise tolerance is significantly improved.